The FDA’s oncology advisory process delivered mixed signals for AstraZeneca’s oral SERD camizestrant as multiple votes questioned different trial strategies for switching patients in HR+/HER2- metastatic breast cancer. In one discussion, the ODAC panel voted 6-3 that available evidence did not support a clinically meaningful benefit for a proposed new switching approach based on ctDNA-detected ESR1 mutations. Separate panel deliberations also surfaced skepticism around paradigm shifts. ODAC discussions reflected concerns that the switching strategy would move earlier in the treatment sequence than current standards, without sufficient evidence to justify that change. Together, the votes underscore how additional regulatory scrutiny can directly affect labeling pathways for oral targeted therapies in breast cancer—especially when the evidentiary threshold hinges on biomarker-driven timing rather than established clinical endpoints.